Logo image of MDCX

MEDICUS PHARMA LTD (MDCX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MDCX - CA58471K2020 - Common Stock

1.41 USD
-0.04 (-2.76%)
Last: 1/14/2026, 9:46:25 AM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MDCX. MDCX was compared to 528 industry peers in the Biotechnology industry. MDCX has a bad profitability rating. Also its financial health evaluation is rather negative. MDCX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year MDCX has reported negative net income.
  • In the past 5 years MDCX always reported negative net income.
  • MDCX had a negative operating cash flow in each of the past 5 years.
MDCX Yearly Net Income VS EBIT VS OCF VS FCFMDCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • The Return On Assets of MDCX (-195.00%) is worse than 87.50% of its industry peers.
  • MDCX has a Return On Equity of -319.45%. This is in the lower half of the industry: MDCX underperforms 73.11% of its industry peers.
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROIC N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDCX Yearly ROA, ROE, ROICMDCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MDCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDCX Yearly Profit, Operating, Gross MarginsMDCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

  • MDCX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MDCX has been increased compared to 5 years ago.
  • There is no outstanding debt for MDCX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MDCX Yearly Shares OutstandingMDCX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDCX Yearly Total Debt VS Total AssetsMDCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • MDCX has an Altman-Z score of -3.92. This is a bad value and indicates that MDCX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of MDCX (-3.92) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.07 indicates that MDCX is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.07, MDCX is not doing good in the industry: 60.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -3.92
ROIC/WACCN/A
WACCN/A
MDCX Yearly LT Debt VS Equity VS FCFMDCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

  • MDCX has a Current Ratio of 2.73. This indicates that MDCX is financially healthy and has no problem in meeting its short term obligations.
  • MDCX has a worse Current ratio (2.73) than 67.80% of its industry peers.
  • MDCX has a Quick Ratio of 2.73. This indicates that MDCX is financially healthy and has no problem in meeting its short term obligations.
  • MDCX has a worse Quick ratio (2.73) than 65.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73
MDCX Yearly Current Assets VS Current LiabilitesMDCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

  • MDCX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.89%, which is quite impressive.
EPS 1Y (TTM)27.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 20.48% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.19%
EPS Next 2Y24.8%
EPS Next 3Y16.36%
EPS Next 5Y20.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDCX Yearly Revenue VS EstimatesMDCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M
MDCX Yearly EPS VS EstimatesMDCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • MDCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDCX Price Earnings VS Forward Price EarningsMDCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDCX Per share dataMDCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

  • MDCX's earnings are expected to grow with 16.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.8%
EPS Next 3Y16.36%

More info and screens

0

5. Dividend

5.1 Amount

  • MDCX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MEDICUS PHARMA LTD

NASDAQ:MDCX (1/14/2026, 9:46:25 AM)

1.41

-0.04 (-2.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-23
Inst Owners9.64%
Inst Owner ChangeN/A
Ins Owners11.16%
Ins Owner Change11.39%
Market Cap31.06M
Revenue(TTM)N/A
Net Income(TTM)-11.16M
Analysts82.22
Price Target22.78 (1515.6%)
Short Float %5.26%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-90.08%
Min EPS beat(2)-119.74%
Max EPS beat(2)-60.43%
EPS beat(4)1
Avg EPS beat(4)-54.37%
Min EPS beat(4)-119.74%
Max EPS beat(4)39.15%
EPS beat(8)2
Avg EPS beat(8)-66.95%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.56%
EPS NQ rev (1m)20.69%
EPS NQ rev (3m)49.27%
EPS NY rev (1m)0%
EPS NY rev (3m)19.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.9
P/tB 8.9
EV/EBITDA N/A
EPS(TTM)-1.67
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z -3.92
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.17%
EPS Next Y51.19%
EPS Next 2Y24.8%
EPS Next 3Y16.36%
EPS Next 5Y20.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-320.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.43%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICUS PHARMA LTD / MDCX FAQ

Can you provide the ChartMill fundamental rating for MEDICUS PHARMA LTD?

ChartMill assigns a fundamental rating of 1 / 10 to MDCX.


What is the valuation status for MDCX stock?

ChartMill assigns a valuation rating of 0 / 10 to MEDICUS PHARMA LTD (MDCX). This can be considered as Overvalued.


What is the profitability of MDCX stock?

MEDICUS PHARMA LTD (MDCX) has a profitability rating of 0 / 10.


Can you provide the financial health for MDCX stock?

The financial health rating of MEDICUS PHARMA LTD (MDCX) is 3 / 10.


What is the earnings growth outlook for MEDICUS PHARMA LTD?

The Earnings per Share (EPS) of MEDICUS PHARMA LTD (MDCX) is expected to grow by 51.19% in the next year.